What is Ardelyx?
Ardelyx operates at the intersection of advanced molecular biology and clinical medicine, focusing on the discovery, development, and commercialization of innovative, first-in-class medicines. The company's market position is defined by its commitment to addressing complex conditions, particularly in the renal and metabolic disease spaces. By leveraging a deep understanding of physiological pathways, Ardelyx has successfully brought IBSRELA to market, providing a tangible therapeutic option for patients. Its ongoing development of XPHOZAH for hyperphosphatemia in chronic kidney disease patients on dialysis further solidifies its role as a key player in specialized healthcare, backed by a history of rigorous clinical trial success and strategic industry partnerships.
How much funding has Ardelyx raised?
Ardelyx has raised a total of $522.5M across 11 funding rounds:
Series A
$26M
Series B
$30M
Multiple Rounds
$100.8M
Share Placement
$77.8M
Stock Offering
$80.4M
Share Placement
$110M
Debt
$50M
Debt
$27.5M
Other Financing Round
$20M
Series A (2008): $26M with participation from CMEA Ventures
Series B (2011): $30M led by CMEA Ventures, New Enterprise Associates, and Amgen Business Development
Corporate Investment (2014): $15M supported by AstraZeneca
Corporate Investment (2014): $25M featuring AstraZeneca
Stock Issuance/Offering (2014): $60.8M backed by Undisclosed
Share Placement (2015): $77.8M with participation from Cormorant Asset Management, RA Capital Advisors, Sabby Capital, New Enterprise Associates, Broadfin Capital, Rock Springs Capital, and Foresite Capital Management
Stock Issuance/Offering (2016): $80.4M led by Undisclosed
Share Placement (2016): $110M supported by New Enterprise Associates, FutureFund, First Manhattan Co., Quadrille Capital, Cormorant Asset Management, Perceptive Advisors, RA Capital Management, Deerfield, DAFNA Capital Management, EcoR1 Capital, and Rock Springs Capital
Debt (2018): $50M featuring Solar Capital and Bridge Bank
Debt (2022): $27.5M backed by SLR Capital Partners
Other Financing Round (2022): $20M with participation from HealthCare Royalty Partners
Key Investors in Ardelyx
New Enterprise Associates
Established in 1977 and headquartered in Menlo Park, California, New Enterprise Associates is a venture capital firm focused on helping entrepreneurs build businesses.
CMEA Ventures
CMEA Capital is a San Francisco-based venture capital firm with a clear focus on life sciences, high technology, and energy and materials investments.
AstraZeneca
AstraZeneca PLC is a global, science-led biopharmaceutical company focused on the discovery, development and commercialisation of prescription medicines.
What's next for Ardelyx?
Looking ahead, Ardelyx is positioned to leverage its recent capital infusion to accelerate the commercial expansion of its existing portfolio and finalize the regulatory and development pathways for its late-stage product candidates. The company's strategic focus remains on maximizing the clinical utility of its tenapanor-based therapies. By maintaining a disciplined approach to resource allocation and continuing to foster relationships with institutional life sciences investors, Ardelyx is well-equipped to navigate the complexities of the biopharmaceutical landscape, aiming to enhance patient outcomes while delivering long-term value to its stakeholders.
See full Ardelyx company page
